RxDoctor Payments Data

Fritz Gutierrez

Family · Lomita, CANPI 1962179135

Payments from drug & device makers

$483in general payments, 2019–2025

Across 24 payments — averaging $20.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$98
  • Lilly USA, LLC$95
  • Bayer$57
  • Pfizer$46
  • Kowa Pharmaceuticals America, Inc.$42
  • Novartis$39
  • plus $105 from 4 others

What the payments were for

  • Food & beverage$483100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk5$98
Lilly USA, LLC4$95
Bayer3$57
Pfizer2$46
Kowa Pharmaceuticals America, Inc.2$42
Novartis2$39
AbbVie2$32
Exact Sciences2$28
Johnson & Johnson1$28
Metacel Pharmaceuticals LLC1$17

How this compares

$483 in reported general payments places this provider in the 60th percentile of 10,634 family providers in California.

See all family providers in California

Medicare billing

Part B allowed, 2024
$538,131
Medicare patients
290
Services billed
4,984

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban91$35,419
JardianceEmpagliflozin33$15,083
EntrestoSacubitril/Valsartan18$6,016
Methenamine Hippurate27$1,354
Sucralfate17$1,318
Atorvastatin Calcium75$908
ZenpepLipase/Protease/Amylase12$884
Gabapentin36$808
Diltiazem Hcl14$722
Levothyroxine Sodium57$693
Hydralazine Hcl17$647
Ondansetron Hcl19$622
Mirtazapine17$533
Metformin Hcl48$450
Furosemide71$435

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$46$35,41991 claims
NovartisEntresto$39$6,01618 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 10,634 family providers in California.

Other family in Lomita

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →